

IN THE SPECIFICATION**AMENDMENTS TO THE SPECIFICATION**

1. Please amend paragraph 18 as follows:

[0018] or a bombesin analog according to the formula:

-Gln-Trp-Ala-Ala-βAla -His-Phe-Nle-NH<sub>2</sub>;  
 -Gln-Trp-Ala-Val-Gly-His-Leu-Ψ(CH<sub>2</sub>-NH)-Leu-NH<sub>2</sub>;  
 -Gln-Trp-Ala-Val-Gly-His-Leu-Ψ(CH<sub>2</sub>-NH)-Phe-NH<sub>2</sub>;  
 -Gln-Trp-Ala-Val-βAla-His-Leu-Leu-NH<sub>2</sub>;  
 -Gln-Trp-Ala-Val-βAla-His-Leu-Nle-NH<sub>2</sub>;  
 -Gln-Trp-Ala-Val-βAla-His-Phe-Nle-NH<sub>2</sub>;  
 -Gln-Trp-Ala-Val-βAla -His-Ala-Nle-NH<sub>2</sub>;  
 -Gln-Trp-Ala-Val-βAla -Ala-Phe-Nle-NH<sub>2</sub>;  
 -Gln-Trp-Ala-Val-Gly-His-Leu-Leu-NH<sub>2</sub>; (SEQ ID NO: 91)  
 -Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH<sub>2</sub>; (SEQ ID NO: 102)  
 -Gln-Trp-Ala-Val-Gly-His-Phe-Met-NH<sub>2</sub>; (SEQ ID NO: 113)  
 -DAla-Gln-Trp-Ala-Val-βAla-His-Phe-Nle-NH<sub>2</sub>;  
 -DPhe-Gln-Trp-Ala-Ala-βAla-His-Phe-Nle-NH<sub>2</sub>;  
 -DPhe-Gln-Trp-Ala-Val-βAla-Ala-Phe-Nle-NH<sub>2</sub>;  
 -DPhe-Gln-Trp-Ala-Val-βAla-His-Phe-Nle-NH<sub>2</sub>;  
 -DPhe-Gln-Trp-Ala-Val-βAla-His-Phe-Nle-NH<sub>2</sub>;  
 -DPhe-Gln-Trp-Ala-Val-βAla-His-Ala-Nle-NH<sub>2</sub>;  
 -DPhe-Gln-Trp-Ala-Val-βAla-His-Leu-Leu-NH<sub>2</sub>;  
 -DPhe-Gln-Trp-Ala-Val-βAla-His-Leu-Nle-NH<sub>2</sub>;  
 -DPhe-Gln-Trp-Ala-Val-Gly-His-Leu-Ψ(CH<sub>2</sub>-NH)-Leu-NH<sub>2</sub>;  
 -DPhe-Gln-Trp-Ala-Val-Gly-His-Leu-Ψ(CH<sub>2</sub>-NH)-Phe-NH<sub>2</sub>;  
 -DPhe-Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH<sub>2</sub>;  
 -DPhe-Gln-Trp-Ala-Val-Gly-His-Phe-Met-NH<sub>2</sub>;  
 -DPhe-Gln-Trp-Ala-Val-Gly-His-Leu-Leu-NH<sub>2</sub>; or

or a pharmaceutically acceptable salt thereof.

2. On page 90 of the specification, please amend the last two sequences as follows:

-HSDAVFTDNYTRLRKQMAVKKLLNSILN-NH<sub>2</sub> (SEQ ID NO: 154)  
 -HSDAVFTDNYTRLRKQMAVKKALNSILN-NH<sub>2</sub> (SEQ ID NO: 165)

3. On page 91 of the specification, please amend the first two sequences as follows:

-HSDAVFTDNYTRLRKQMAVKKFLNSILN-NH<sub>2</sub> (SEQ ID NO: 176)

-HSDAVFTDNYTRLRKQMAVKKYLSILN-NH<sub>2</sub> (SEQ ID NO: ~~187~~)

4. On page 127 of the specification, please amend the sequences as follows:

-HSDAVFTDNYTRLRKQMAVKKYLSILN-NH<sub>2</sub> (SEQ ID NO: ~~187~~)

-HSDAVFTDNYTRLRKQMAVKKFLNSILN-NH<sub>2</sub> (SEQ ID NO: ~~176~~)

-HSDAVFTDNYTRLRKQMAVKKALNSILN-NH<sub>2</sub> (SEQ ID NO: ~~165~~)

-HSDAVFTDNYTRLRKQMAVKKLLNSILN-NH<sub>2</sub> (SEQ ID NO: ~~154~~)

5. On page 183 of the specification, please amend the sequences as follows:

-HSDAVFTDNYTRLRKQMAVKKYLSILN-NH<sub>2</sub> (SEQ ID NO: ~~187~~)

-HSDAVFTDNYTRLRKQMAVKKALNSILN-NH<sub>2</sub> (SEQ ID NO: ~~165~~)

-HSDAVFTDNYTRLRKQMAVKKLLNSILN-NH<sub>2</sub> (SEQ ID NO: ~~154~~)

6. Please delete the original Sequence Listing and insert the Substitute Sequence Listing included herewith.